Biopure (BPUR) Receives Delisting Notification From NASDAQ
More News related to BPUR
- Biopure (BPUR) Receives Delisting Notification From NASDAQ
- Biopure (BPUR) Receives Nasdaq Delisting Notice
- Biopure (BPUR) Sees Upside Action
- Biopure (BPUR) Hires Newbury Piret & Co. to Help Explore Strategic Options
- FDA Advises US Navy That It May Not Initiate A Clinical Trial of Biopure's Product Hemopure
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Biopure Corporation (Nasdaq: BPUR) has received notice from The Nasdaq Stock Market, by letter dated July 17, 2009, that its common stock would be delisted from Nasdaq. The notice stated that because of concerns raised by the Company's filing for protection under Chapter 11 of the Bankruptcy Code, trading would be suspended at the opening of business on July 28, 2009.
The company does not intend to appeal this decision.
Biopure Corporation develops and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
